IP Library › Patent Application 11791242
Patent Application
App. No. 11/791,242

Drug Combination Comprising A Selective Serotonin Reuptake Inhibitor And A Glucocorticoid Receptor Antagonist For The Treatment Of Depression

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
11/791,242
Abstract

The invention provides for a combination comprising an amount of an SSRI, or a pharmaceutically acceptable salt or solvate thereof, and an amount of a GR antagonist, or a pharmaceutically acceptable salt or solvate thereof, optionally in association with one or more pharmaceutically acceptable carriers for use as therapy for depression and related disorders.

Claims (8)

1 . A combination comprising an amount of a serotonin reuptake inhibitor, or a pharmaceutically acceptable salt or solvate thereof, and an amount of a glucocorticoid receptor antagonist, or a pharmaceutically acceptable salt or solvate thereof, optionally in association with one or more pharmaceutically acceptable carriers.

2 - 6 . (canceled)

7 . A method for the treatment of an individual of a vertebrate species suffering from depression or a related disorder, which method of treatment comprises administering an effective amount of a serotonin reuptake inhibitor in combination with a glucocorticoid receptor antagonist.

8 . The combination according to claim 1 , wherein the serotonin reuptake inhibitor is selected from the group consisting of citalopram, S-citalopram, clomipramine, fluoxetine, fluvoxamine, paroxetine and sertraline.

9 . The combination according to claim 1 , wherein the glucocorticoid receptor antagonist is selected from the group consisting of (11β,17β)-11-[4-(dimethylamino)phenyl]-17-hydroxy-17-(1-propynyl)-estra-4,9-dien-3-one), (11β,17β)-11-(1,3-benzodioxol-5-yl)-17-hydroxy-17-(1-propynyl)-estra-4,9-dien-3-one, (11β,17α)-11-14-(dimethylamino)phenyl-17-hydroxy-21-14-(methylsulfonyl)phenyl-19-norpregna-4,9-dien-20-yn-3-one and ketoconazole.

10 . The combination according to claim 1 , wherein the glucocorticoid receptor antagonist is (11β,17β)-11-(1,3-benzodioxol-5-yl)-17-hydroxy-17-(1-propynyl)-estra-4,9-diene-3-one.

11 . The method of claim 7 , wherein the vertebrate is a mammal.

12 . The method of claim 11 , wherein the mammal is a human.

Assignments (1)
MERGER Recorded Dec 1, 2011
From: N.V. ORGANON
To: MSD OSS B.V.
Reel/Frame 027307/0482 →